SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test
Capricor (CAPR) reported positive results from its Hope-3 trial, showing Deramiocel slowed decline in arm and hand function. CEO Linda Marban expressed confidence ahead of the PDUFA date. Retail sentiment on Stocktwits was bullish for both CAPR and Summit Therapeutics (SMMT), despite SMMT's stock plunging 19% year-to-date and CAPR falling 67%.
How this was made

The 30-second read
Why it matters
The trial data provides fresh, material information that could influence CAPR's stock price ahead of the upcoming FDA decision.
Market read
Biotech investors focus on trial outcomes; this news may trigger short‑term price movement.
What to watch
Potential safety concerns or manufacturing scale‑up challenges not addressed in the release.
Background
The article discusses retail sentiment on StockTwits and reports Capricor's Phase 2 trial results for Deramiocel, a therapy for arm and hand function decline.
Ticker impact
Capricor reported Phase 2 trial data showing Deramiocel slowed functional decline versus placebo.
likely upward pressure as market prices in potential approval expectations
Clinical data is a material catalyst; investors often bid up biotech stocks on favorable results.
Market effects
May lift sentiment for other gene‑therapy and rare‑disease biotech firms.
US biotech sector could see modest gains.
Limited to investors tracking FDA‑regulated therapeutics.
Counterpoint
Skeptics may wait for FDA decision before taking positions, citing past trial‑to‑approval attrition.
Key entities
- companyCapricor Therapeutics
Biotech firm developing Deramiocel.

